352 related articles for article (PubMed ID: 27124048)
1. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
McCleary NJ; Odejide O; Szymonifka J; Ryan D; Hezel A; Meyerhardt JA
Clin Colorectal Cancer; 2013 Mar; 12(1):62-9. PubMed ID: 23102897
[TBL] [Abstract][Full Text] [Related]
4. [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Qiu MZ; Teng KY; Ruan DY; Li YH; Chen XQ; Pan ZZ; He YJ; Wan DS; Xu RH
Ai Zheng; 2009 Jul; 28(7):743-8. PubMed ID: 19624903
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
8. Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
Wu J; Ge XX; Zhu W; Zhi Q; Xu MD; Duan W; Chen K; Gong FR; Tao M; Shou LM; Wu MY; Wang WJ
Mol Med Rep; 2019 Mar; 19(3):2330-2340. PubMed ID: 30664202
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
McCleary NJ; Meyerhardt JA; Green E; Yothers G; de Gramont A; Van Cutsem E; O'Connell M; Twelves CJ; Saltz LB; Haller DG; Sargent DJ
J Clin Oncol; 2013 Jul; 31(20):2600-6. PubMed ID: 23733765
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
13. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
[TBL] [Abstract][Full Text] [Related]
14. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
16. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
18. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
[TBL] [Abstract][Full Text] [Related]
19. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]